India Corporate Law Update: CSR ZCZP Route, CCFS-2026 Amnesty & RBI TReDS Overhaul
Three regulatory updates from the Ministry of Corporate Affairs and the Reserve Bank of India that reshape how foreign companies manage CSR spending, compliance backlogs, and MSME receivables financing in India.
Recent Court Decisions in Arbitration
Three Supreme Court decisions and one Allahabad High Court decision delivered between April and July 2026
India Pharma & Life Sciences IP Update │ April–June 2026 Cases & Standards
From AbbVie’s Venetoclax setback to tougher impurity limits under Indian Pharmacopoeia 2026, this Q2 update distils the key patent, trademark and regulatory moves reshaping India’s pharma and life-sciences arena—and what they mean for your compliance strategy.
India’s IBC (Amendment) Act 2026 — What Foreign Counsel Should Know
India’s IBC (Amendment) Act, 2026 changes the way foreign creditors should assess Indian counterparty risk. From cross-border insolvency and group insolvency to CIIRP, mandatory admission timelines and guarantee enforcement, the Amendment reshapes recovery strategy for India-linked transactions.
Foreign Summary Judgments in India: 5 Clauses to Reread After Messer Griesheim case
This issue walks through what the Court actually said, why summary procedures in particular now fail the Indian enforceability test, the five contract clauses every foreign-counterparty agreement should be re-read against this month, and the choice between foreign-court and arbitration forums going forward. If you have an Indian counterparty in any of your cross-border contracts, […]
A practical guide to CCFS-2026 for foreign-owned Indian subsidiaries
A 90-day window letting foreign-owned Indian subsidiaries clear their ROC compliance backlog at roughly 10% of standard penalty fees, written for foreign GCs, CFOs, and directors who need to act before the 15 July 2026 close.
What Foreign Counsel Need to Know Before Advising Clients on India-Facing Arbitration
Recent Supreme Court decisions on Sections 34/37 review, arbitrability where consent is disputed, and enforcement of foreign awards under Section 48.
Recent Developments in Pharma & Life Sciences IP in India
Quarter 1 of 2026 saw major court and policy developments shaping pharma and life sciences IP in India. This March edition covers biosimilar injunction standards, post-expiry patent revocation, export-manufacturing risk, key pharma trademark disputes, and fresh CGPDTM/DPIIT updates—with practical takeaways for innovators, generics, and healthcare brands.
Digital Personal Data Protection Rules 2025: Privacy, Competition & Corporate Compliance
India’s Digital Personal Data Protection (DPDP) Rules, 2025 mark a clear shift towards enforceable privacy governance, with the Data Protection Board now operational. This edition explains what the framework means for foreign businesses handling personal data linked to individuals in India, where privacy risk starts to overlap with competition law, and how DPDP compares with the EU GDPR. You will also find a practical readiness checklist, key takeaways, and a phased compliance timeline running through May 2027. Read the full newsletter for the details.
Arbitration in India: Balancing Autonomy and Judicial Oversight
Four decisions. Clear signals. This January 2026 disputes newsletter highlights fresh arbitration and commercial dispute rulings and the takeaways businesses should act on.
